Brokerages Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Target Price at $5.25

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been given an average rating of “Hold” by the nine research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $5.25.

Several analysts have weighed in on the stock. Wells Fargo & Company upped their price objective on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Tuesday, October 14th.

Maravai LifeSciences Stock Up 1.8%

Shares of NASDAQ MRVI opened at $3.33 on Friday. The stock has a market cap of $851.51 million, a PE ratio of -3.96 and a beta of 0.32. The business has a fifty day moving average of $3.40 and a two-hundred day moving average of $2.89. Maravai LifeSciences has a 52-week low of $1.66 and a 52-week high of $6.21. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.56 and a current ratio of 5.29.

Maravai LifeSciences (NASDAQ:MRVI) last posted its earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%.The firm had revenue of $41.63 million during the quarter, compared to the consensus estimate of $49.02 million. As a group, equities research analysts expect that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Maravai LifeSciences news, Director Gregory T. Lucier bought 51,472 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were bought at an average price of $3.70 per share, for a total transaction of $190,446.40. Following the completion of the acquisition, the director owned 106,595 shares of the company’s stock, valued at approximately $394,401.50. This trade represents a 93.38% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Bernd Brust bought 216,212 shares of the stock in a transaction dated Thursday, November 13th. The stock was acquired at an average price of $3.25 per share, with a total value of $702,689.00. Following the completion of the purchase, the chief executive officer owned 466,771 shares of the company’s stock, valued at $1,517,005.75. This represents a 86.29% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 566,771 shares of company stock worth $1,880,244. Insiders own 2.11% of the company’s stock.

Hedge Funds Weigh In On Maravai LifeSciences

Institutional investors have recently modified their holdings of the stock. Sprott Inc. acquired a new position in shares of Maravai LifeSciences during the third quarter worth approximately $29,000. Callan Family Office LLC acquired a new stake in shares of Maravai LifeSciences in the second quarter valued at approximately $25,000. Ethic Inc. bought a new position in Maravai LifeSciences in the 2nd quarter worth approximately $26,000. Quantessence Capital LLC acquired a new position in Maravai LifeSciences during the 3rd quarter worth $31,000. Finally, Abel Hall LLC bought a new position in Maravai LifeSciences in the 3rd quarter valued at $33,000. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.